Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
13.90
+0.19 (1.39%)
At close: Aug 13, 2025, 4:00 PM
13.96
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:39 AM EDT
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $18.17M in the quarter ending June 30, 2025, with 49,002.70% growth. This brings the company's revenue in the last twelve months to $232.84M, up 85,820.30% year-over-year. In the year 2024, Keros Therapeutics had annual revenue of $3.55M with 2,250.99% growth.
Revenue (ttm)
$232.84M
Revenue Growth
+85,820.30%
P/S Ratio
2.39
Revenue / Employee
$1,377,775
Employees
169
Market Cap
564.55M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
KROS News
- 7 days ago - Keros to Exclusively Prioritize the Clinical Advancement of KER-065 - GlobeNewsWire
- 7 days ago - Keros Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - GlobeNewsWire
- 2 months ago - ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal - PRNewsWire
- 2 months ago - Keros Announces Return of $375 Million in Excess Capital to Stockholders - GlobeNewsWire
- 2 months ago - Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - GlobeNewsWire
- 2 months ago - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees - GlobeNewsWire